The True Promise of Quality by Design: Risks & Rewards

Add bookmark
In this exclusive interview Jesús Zurdo, Head of Innovation, Biopharma Development, Lonza Biologics, speaks to Andrea Charles from Pharma IQ about improving the developability of biopharmaceuticals, the advantages of implementing early risk assessment and enhancing manufacture through Quality By Design (QbD). Zurdo also shares his views on the future and true promise of QbD. Pharma IQ: What sort of current trends have you witnessed, with regards to improving the developability of bio...
To continue reading this story get free access

Upcoming Events

DigIT Pharma 2026 | AI Commercial, Medical & Patient Care

September 9 - 10, 2026

Steigenberger Airport Hotel Berlin, Deutschland

DigIT Pharma 2026 | AI Commercial, Medical & Patient Care

Pharmaceutical Launch Excellence Summit US

September 30 - October 1, 2026

Hyatt Regency Boston Harbor, Boston, US

Pharmaceutical Launch Excellence Summit US

Pharmaceutical Launch Excellence Summit

1 - 3 December, 2026

Novotel Amsterdam City, Netherlands

Pharmaceutical Launch Excellence Summit

SmartLab Exchange Europe

22 - 23 February 2027

Leonardo Royal Hotel Amsterdam, Netherlands

SmartLab Exchange Europe

Latest Webinars

Pharma IQ's Power List 2022: In conversation with pharma's top leaders

2022-10-18

02:00 PM - 03:00 PM BST

Join us to hear from the most influential people in pharma today, as voted for by you

A post-pandemic 3D view of the patient and supply journey

2022-06-01

04:30 PM - 05:30 PM CET

In this panel discussion with experts from 4G Clinical, THREAD Research and World Courier, learn how...

Discover how targeted radiotherapy induced toxicity can be identified with imaging

2022-04-28

01:00 PM - 02:00 PM EST

This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the...

Recommended